These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 36327527)

  • 1. Nivolumab plus ipilimumab plus cabozantinib triplet combination for patients with previously untreated advanced renal cell carcinoma: Results from a discontinued arm of the phase III CheckMate 9ER trial.
    Apolo AB; Powles T; Escudier B; Burotto M; Zhang J; Simsek B; Scheffold C; Motzer RJ; Choueiri TK
    Eur J Cancer; 2022 Dec; 177():63-71. PubMed ID: 36327527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial.
    Motzer RJ; Powles T; Burotto M; Escudier B; Bourlon MT; Shah AY; Suárez C; Hamzaj A; Porta C; Hocking CM; Kessler ER; Gurney H; Tomita Y; Bedke J; Zhang J; Simsek B; Scheffold C; Apolo AB; Choueiri TK
    Lancet Oncol; 2022 Jul; 23(7):888-898. PubMed ID: 35688173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial.
    Powles T; Burotto M; Escudier B; Apolo AB; Bourlon MT; Shah AY; Suárez C; Porta C; Barrios CH; Richardet M; Gurney H; Kessler ER; Tomita Y; Bedke J; George S; Scheffold C; Wang P; Fedorov V; Motzer RJ; Choueiri TK
    ESMO Open; 2024 May; 9(5):102994. PubMed ID: 38642472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.
    Motzer RJ; Rini BI; McDermott DF; Arén Frontera O; Hammers HJ; Carducci MA; Salman P; Escudier B; Beuselinck B; Amin A; Porta C; George S; Neiman V; Bracarda S; Tykodi SS; Barthélémy P; Leibowitz-Amit R; Plimack ER; Oosting SF; Redman B; Melichar B; Powles T; Nathan P; Oudard S; Pook D; Choueiri TK; Donskov F; Grimm MO; Gurney H; Heng DYC; Kollmannsberger CK; Harrison MR; Tomita Y; Duran I; Grünwald V; McHenry MB; Mekan S; Tannir NM;
    Lancet Oncol; 2019 Oct; 20(10):1370-1385. PubMed ID: 31427204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial.
    Tykodi SS; Gordan LN; Alter RS; Arrowsmith E; Harrison MR; Percent I; Singal R; Van Veldhuizen P; George DJ; Hutson T; Zhang J; Zoco J; Johansen JL; Rezazadeh Kalebasty A
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35210307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial.
    George DJ; Spigel DR; Gordan LN; Kochuparambil ST; Molina AM; Yorio J; Rezazadeh Kalebasty A; McKean H; Tchekmedyian N; Tykodi SS; Zhang J; Askelson M; Johansen JL; Hutson TE
    BMJ Open; 2022 Sep; 12(9):e058396. PubMed ID: 36104138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study.
    Amin A; Plimack ER; Ernstoff MS; Lewis LD; Bauer TM; McDermott DF; Carducci M; Kollmannsberger C; Rini BI; Heng DYC; Knox J; Voss MH; Spratlin J; Berghorn E; Yang L; Hammers HJ
    J Immunother Cancer; 2018 Oct; 6(1):109. PubMed ID: 30348216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
    Choueiri TK; Powles T; Burotto M; Escudier B; Bourlon MT; Zurawski B; Oyervides Juárez VM; Hsieh JJ; Basso U; Shah AY; Suárez C; Hamzaj A; Goh JC; Barrios C; Richardet M; Porta C; Kowalyszyn R; Feregrino JP; Żołnierek J; Pook D; Kessler ER; Tomita Y; Mizuno R; Bedke J; Zhang J; Maurer MA; Simsek B; Ejzykowicz F; Schwab GM; Apolo AB; Motzer RJ;
    N Engl J Med; 2021 Mar; 384(9):829-841. PubMed ID: 33657295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial.
    Yau T; Zagonel V; Santoro A; Acosta-Rivera M; Choo SP; Matilla A; He AR; Cubillo Gracian A; El-Khoueiry AB; Sangro B; Eldawy TE; Bruix J; Frassineti GL; Vaccaro GM; Tschaika M; Scheffold C; Koopmans P; Neely J; Piscaglia F
    J Clin Oncol; 2023 Mar; 41(9):1747-1757. PubMed ID: 36512738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Grade 3/4 Adverse Event Costs of Immuno-oncology Combination Therapies for Previously Untreated Advanced Renal Cell Carcinoma.
    McGregor B; Geynisman DM; Burotto M; Porta C; Suarez C; Bourlon MT; Del Tejo V; Du EX; Yang X; Sendhil SR; Betts KA; Huo S
    Oncologist; 2023 Jan; 28(1):72-79. PubMed ID: 36124890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nivolumab monotherapy or combination with ipilimumab with or without cobimetinib in previously treated patients with pancreatic adenocarcinoma (CheckMate 032).
    Callahan M; Amin A; Kaye FJ; Morse MA; Taylor MH; Peltola KJ; Sharma P; O'Reilly EM; Meadows Shropshire S; O'Brien S; Tschaika M; Le DT
    J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38316517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial.
    Cella D; Motzer RJ; Suarez C; Blum SI; Ejzykowicz F; Hamilton M; Wallace JF; Simsek B; Zhang J; Ivanescu C; Apolo AB; Choueiri TK
    Lancet Oncol; 2022 Feb; 23(2):292-303. PubMed ID: 35032437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up.
    Tomita Y; Kondo T; Kimura G; Inoue T; Wakumoto Y; Yao M; Sugiyama T; Oya M; Fujii Y; Obara W; Motzer RJ; Uemura H
    Jpn J Clin Oncol; 2020 Jan; 50(1):12-19. PubMed ID: 31633185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial.
    Motzer RJ; Escudier B; McDermott DF; Arén Frontera O; Melichar B; Powles T; Donskov F; Plimack ER; Barthélémy P; Hammers HJ; George S; Grünwald V; Porta C; Neiman V; Ravaud A; Choueiri TK; Rini BI; Salman P; Kollmannsberger CK; Tykodi SS; Grimm MO; Gurney H; Leibowitz-Amit R; Geertsen PF; Amin A; Tomita Y; McHenry MB; Saggi SS; Tannir NM
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32661118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exposure-Response Analysis to Support Nivolumab Once Every 4 Weeks Dosing in Combination with Cabozantinib in Renal Cell Carcinoma.
    Hamuro L; Hu Z; Passarell J; Barcomb H; Zhang J; Goldstein S; Bello A; Roy A; Zhu L
    Clin Cancer Res; 2022 Apr; 28(8):1603-1613. PubMed ID: 34980597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy.
    Choueiri TK; Kluger H; George S; Tykodi SS; Kuzel TM; Perets R; Nair S; Procopio G; Carducci MA; Castonguay V; Folefac E; Lee CH; Hotte SJ; Miller WH; Saggi SS; Lee CW; Desilva H; Bhagavatheeswaran P; Motzer RJ; Escudier B
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36328377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920.
    Emamekhoo H; Olsen MR; Carthon BC; Drakaki A; Percent IJ; Molina AM; Cho DC; Bendell JC; Gordan LN; Rezazadeh Kalebasty A; George DJ; Hutson TE; Arrowsmith ER; Zhang J; Zoco J; Johansen JL; Leung DK; Tykodi SS
    Cancer; 2022 Mar; 128(5):966-974. PubMed ID: 34784056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma.
    Choueiri TK; Powles T; Albiges L; Burotto M; Szczylik C; Zurawski B; Yanez Ruiz E; Maruzzo M; Suarez Zaizar A; Fein LE; Schutz FA; Heng DYC; Wang F; Mataveli F; Chang YL; van Kooten Losio M; Suarez C; Motzer RJ;
    N Engl J Med; 2023 May; 388(19):1767-1778. PubMed ID: 37163623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial.
    Albiges L; Tannir NM; Burotto M; McDermott D; Plimack ER; Barthélémy P; Porta C; Powles T; Donskov F; George S; Kollmannsberger CK; Gurney H; Grimm MO; Tomita Y; Castellano D; Rini BI; Choueiri TK; Leung D; Saggi SS; Lee CW; McHenry MB; Motzer RJ
    Eur Urol; 2022 Mar; 81(3):266-271. PubMed ID: 34750035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial.
    Albiges L; Tannir NM; Burotto M; McDermott D; Plimack ER; Barthélémy P; Porta C; Powles T; Donskov F; George S; Kollmannsberger CK; Gurney H; Grimm MO; Tomita Y; Castellano D; Rini BI; Choueiri TK; Saggi SS; McHenry MB; Motzer RJ
    ESMO Open; 2020 Nov; 5(6):e001079. PubMed ID: 33246931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.